# Phase II Neoadjuvant Pyrotinib Combined with Neoadjuvant Chemotherapy in HER2-low-expressing and HR Positive Early or Locally Advanced Breast Cancer: a Single-arm, Non-randomized, Single-center, Open Label Trial

> **NCT05165225** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University** · enrollment: 48 (estimated)

## Conditions studied

- Breast Cancer
- HER2-low-expressing Breast Cancer
- Hormone Receptor-positive Breast Cancer
- Neoadjuvant Therapy

## Interventions

- **DRUG:** Pyrotinib + epirubicin and cyclophosphamide followed by docetaxel treatment

## Key facts

- **NCT ID:** NCT05165225
- **Lead sponsor:** Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-07-13
- **Primary completion:** 2023-09-30
- **Final completion:** 2028-03-31
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2024-11-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05165225

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05165225, "Phase II Neoadjuvant Pyrotinib Combined with Neoadjuvant Chemotherapy in HER2-low-expressing and HR Positive Early or Locally Advanced Breast Cancer: a Single-arm, Non-randomized, Single-center, Open Label Trial". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05165225. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*